Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle
NCT ID: NCT05131555
Last Updated: 2024-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
14 participants
INTERVENTIONAL
2021-08-16
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Role of Histamine in Muscle Protein Synthesis Following Resistance Training
NCT06152497
Histamine as a Molecular Transducer of Adaptation to Exercise
NCT05206227
Histamine H1/H2 Receptors and Training Adaptations
NCT04450134
Histamines and Central Hemodynamics
NCT07285031
Multiple Dose, Double-Blind, Placebo and Active Controlled Study of Pharmacokinetics of Diractin® as Well as Safety and Efficacy for the Treatment of Muscle Soreness
NCT00745771
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1: Placebo
lactose
Placebo: Placebo + exercise training.
Oral placebo Exercise training: Interval-based cycling exercise
H1 blockade
540 mg Fexofenadine
H1 blockade: H1 receptor antagonist + exercise training
H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
H2 blockade
40 mg Famotidine
H2 Blockade: H2 receptor antagonist + exercise training
H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo: Placebo + exercise training.
Oral placebo Exercise training: Interval-based cycling exercise
H1 blockade: H1 receptor antagonist + exercise training
H1 blockade: oral blockade Exercise training: Interval-based cycling exercise
H2 Blockade: H2 receptor antagonist + exercise training
H2 blockade: oral blockade Exercise training: Interval-based cycling exercise
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-45 years
* not to medium physically active
Exclusion Criteria
* Chronic disease
* Supplement or medication intake
* Seasonal allergies
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Foundation Flanders
OTHER
University Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wim Derave, Professor
Role: PRINCIPAL_INVESTIGATOR
University Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of movement and sports sciences, Ghent University, Belgium
Ghent, Oost-Vlaanderen, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AET - BC-10237
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.